Luye Group 
Welcome,         Profile    Billing    Logout  
 36 Products   29 Diseases   36 Products   123 Trials   3033 News 


«12...1920212223242526272829...3334»
  • ||||||||||  poziotinib (HM 78136B) / Spectrum, Hanmi
    Journal, Cancer stem cells:  Poziotinib suppresses ovarian cancer stem cell growth via inhibition of HER4-mediated STAT5 pathway. (Pubmed Central) -  Nov 26, 2020   
    Interestingly, HER4 was overexpressed in ovarian CSCs and Poziotinib reduced the phosphorylation of STAT5, AKT, and ERK, which are regulated by HER4. Our results suggest that HER4 may be a promising therapeutic target for ovarian CSCs, and that poziotinib may be an effective therapeutic option for the prevention of ovarian cancer recurrence.
  • ||||||||||  paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
    Review, Journal, PARP Biomarker, IO Biomarker:  Drugs in development for small cell lung cancer. (Pubmed Central) -  Nov 21, 2020   
    Aurora A kinase (AAK) inhibitors showed initial activity when given with paclitaxel but in randomized studies, failed to improve outcomes over paclitaxel plus placebo...Delta-like protein 3 (DLL3) is an appealing therapeutic target given its selective expression on SCLC cells, but after initial exciting results, the antibody-drug conjugate (ADC) Rovalpituzumab tesirine (Rova-T) did not have a favorable efficacy to toxicity profile in randomized trials...Targeting angiogenesis has yielded modest improvements in the past but newer agents such as anlotinib are renewing interest. While the current therapeutic landscape beyond chemo-immunotherapy remains the same as it was decades ago, drug development for SCLC is rapidly moving forward and promises to deliver the needed novel agents in the very near future.
  • ||||||||||  rotigotine XR microspheres (LY03003) / Luye Pharma
    Journal:  The Effect of Rotigotine Extended-Release Microspheres Alone or With Celecoxib on the Inflammatory Pain. (Pubmed Central) -  Nov 18, 2020   
    Clinical trials of rotigotine extended-release microspheres (RTGT-MS), which provides a sustained release of rotigotine for near 2 weeks in vivo, have been conducted in the treatment of Parkinson's disease (PD)...Chlorpromazine, a dopamine receptor blocker, not only weakened the analgesic effect of RTGT-MS, but also increased the levels of cAMP, PKA, COX-2, and PGE2. These findings provide a rationale for the combination of RTGT-MS and celecoxib in the treatment of PD, which may reduce the dose of celecoxib, thereby lowering the incidence of adverse effects and improving the pain management in PD patients.
  • ||||||||||  Pozenveo (poziotinib) / Assertio
    Trial completion date, Trial termination, Trial primary completion date, EGFR exon 20, HER2 exon 20, Metastases:  Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation (clinicaltrials.gov) -  Nov 16, 2020   
    P2,  N=5, Terminated, 
    These findings provide a rationale for the combination of RTGT-MS and celecoxib in the treatment of PD, which may reduce the dose of celecoxib, thereby lowering the incidence of adverse effects and improving the pain management in PD patients. Trial completion date: Aug 2020 --> Apr 2020 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2020 --> Apr 2020; Study termination by the Sponsor
  • ||||||||||  Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Clinical, Clinical guideline, Journal, IO Biomarker:  SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019). (Pubmed Central) -  Nov 2, 2020   
    Reinduction with platinum-etoposide is the recommended regimen in patients with sensitive relapse (≥ 3 months) and new drugs such as lurbinectedin and immunotherapy are new treatment options. New biomarkers and new clinical trials designed according to the new classification of SCLC subtypes defined by distinct gene expression profiles are necessary.
  • ||||||||||  poziotinib (HM 78136B) / Spectrum Pharma, mobocertinib (TAK-788) / Takeda
    Journal, Tumor Mutational Burden:  Urothelial Cancer Harbors EGFR and HER2 Amplifications and Exon 20 Insertions. (Pubmed Central) -  Oct 30, 2020   
    EGFR and ERBB2 were present in 0.7% and 0.5% of UC overall and collectively define a small, but distinct subsets of UC with infrequent co-occurrence of other drivers and low TMB. Given recent promising clinical studies of inhibitors with activity against exon 20 insertions in NSCLC, consideration should be given to developing a trial inclusive of patients with UC harboring these alterations.
  • ||||||||||  utidelone IV (UTD1) / Beijing Biostar Technologies
    Trial completion date, Trial primary completion date, Monotherapy, Metastases:  Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Colorectal Cancer (clinicaltrials.gov) -  Oct 26, 2020   
    P2,  N=30, Recruiting, 
    Given recent promising clinical studies of inhibitors with activity against exon 20 insertions in NSCLC, consideration should be given to developing a trial inclusive of patients with UC harboring these alterations. Trial completion date: Jul 2020 --> Jun 2021 | Trial primary completion date: Apr 2020 --> Apr 2021
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Enrollment open, Trial initiation date, Combination therapy, PD(L)-1 Biomarker:  LUPER: Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer. (clinicaltrials.gov) -  Oct 19, 2020   
    P1/2,  N=42, Recruiting, 
    The results provide evidence of additional onco-therapeutic actions for these drugs. Not yet recruiting --> Recruiting | Initiation date: May 2020 --> Sep 2020